Additionally, chronic pharmacological inhibition [22] or genetic ablation [23,24] of QC in transgenic mouse and drosophila models of AD resulted in reduced pE-Abeta peptide generation and in ameliorated behavioral deficits, while QC overexpression aggravated neuropathology and cognitive dysfunction in transgenic mice [24]. This evidence concerns the gene APP and Alzheimer disease.